To: aknahow who wrote (226 ) 9/28/2001 2:16:03 PM From: nigel bates Read Replies (1) | Respond to Because, as far as I am aware, they are for bacterial products of bacterial cell expression, not human cell expression.Berkeley, CA -- March 22, 2001 -- XOMA Ltd. (NASDAQ: XOMA), a biopharmaceutical company that develops and manufactures innovative products to treat cancer, immunological and inflammatory disorders, and infectious diseases, today announced it has been issued a new U.S. patent with method claims that broadly cover the secretion of antibodies from bacteria .bacteria and are capable of antigen binding. This is the sixth patent issued to XOMA in its antibody expression family of patents and the third patent in this family that broadly covers methods for the secretion of functional immunoglobulins from bacteria , including single-chain antibodies and antibody fragments.Bacterial antibody expression is a key enabling technology for the discovery and selection, as well as the development and manufacture, of many recombinant antibody-based pharmaceuticals. Antibody discovery by phage display technology, for example, depends upon expressing antibody domains in bacteria as properly folded, functional, secreted proteins, as described in XOMA’s patent claims.bacterial cell expression system. A number of foreign patents have been granted, which, along with pending applications, correspond to the issued U.S. patents.bacterial cell expression system for use by biopharmaceutical developers. A licensed system may include the patented araB promoter, which allows efficient control of the expression of the desired product, and the patented pelB secretion signal, which improves yields and reduces recovery and purification costs. A genetically engineered E. coli host-cell line that complements the araB and pelB technologies is also available as part of the system, along with an easy-to-use fermentation process and nutrient medium formula to support the cells. bacterial cell expression technology for use by biotechnology and pharmaceutical companies worldwide. These companies are applying the system to select and produce recombinant products in development, including therapeutic and diagnostic antibodies, vaccines, toxins, and enzymes, as well as recombinant expression vectors for research use. License terms typically include licensing fees, maintenance and milestone payments, and royalties on future income streams of selected and developed products...
